


How to overcome the challenges in biologics development & quality control

The global biologics market is booming. By 2025, it is expected to reach a value of \$450B. Though biologics are currently celebrating momentum, their development remains greatly challenging. Even small variations in the highly complex structure of biologics can already have an effect on the biologics' safety, efficacy, and function. This can cause severe immune reactions in patients and trigger life-threatening conditions. It is therefore essential to address the challenges in biologics development as early as possible.



WORKFLOW OF BIOLOGICS DEVELOPMENT

| Product Discovery | Process Development | Clinical Development | | | |
|--------------------------------------|------------------------------------------------------------------------------|-----------------------------|----------------|---------------------------------------------|------------|
| | | PHASE I | PHASE II | PHASE III | PHASE IV |
| Target Selection & Identification | Cell Line Development | Proof of | Concept | | |
| Candidate Selection | Animal Studies: | Safety | Safety | Safety | |
| | Toxicity, Efficacy, Safety | | | | |
| Optimization | Pharmacokinetic (PK) & Pharmacodynamic (PD) Formulation Development | GMP Production | Efficacy | Efficacy | |
| Early System | Stability Studies | Stability Studies | РК | Full GMP | A |
| Biology Studies | | | | Production | U U |
| Biomarker Identification | Product Characterization | Product Characterization | Scale-up | Quality Control | COMMERCIAL |
| Preclinical Testing | Process Characterization | PK & PD in | Stability | Stability Studies | 20 |
| | | Healthy Humans | Studies | | Ŭ |
| Cell-Based Assays: Early | | Method Validation | Dose Titration | Product Release Testing | |
| Toxicity, Efficacy, Safety | | | | | |
| | | IND | | Process Validation & Characterization | |
| | | Regula | tory Compli | ance ——— | |
| | 10-1 | 2 YEARS - | | | |
| | | - 20-25 YEA | RS | | |

Biologics development & quality control come with a number of challenges...



If anything in the development of biologics goes wrong, it can result in manufacturing failures, severe time delays, regulatory issues, and risks for the patient. One change triggers a cascade of changes!

How do we support biologics development & quality control?

To prevent contamination, we have



40+ years of sterility testing expertise

- Developed the Monocyte Activation Test (MAT) in vitro test kits for pyrogen testing, to move away from animal-based tests
- A complete portfolio for microbiology quality control monitoring of air, surfaces, people, raw materials, in-process samples & the final product



To address reference standard challenges, we have

• Developed a comprehensive portfolio of 100+ common impurities often found in extractables & leachables studies

To free more resources for method development, we use



- The SigmaMAb ADC Mimic as a non-toxic drug mimic for mass spectrometry & high-performance liquid chromatography
- The SOLu-Trypsin enzyme for mass spectrometry. SOLu-Trypsin is a convenient, ready-to-use trypsin solution for protein digestion & is stable in solution when refrigerated

To support our customers through the regulatory maze, we



- Have decades of regulatory experience
- Comply with numerous global regulatory standards, e.g. ISO, ACS, USP, PhEur, JP, FDA CFR
- Offer products with a range of specifications & accreditations

Meet our Life science brands

Millipore_®

The Millipore[®] portfolio of MilliporeSigma offers an ecosystem of industry-leading products and services, spanning preparation, separation, filtration and monitoring – all of which are deeply rooted in quality, reliability and timetested processes. Our proven products, regulatory and application expertise are a strong foundation you can rely on to consistently perform at the highest level.

Supelco_®

The Supelco[®] portfolio of analytical solutions of MilliporeSigma is developed by analytical chemists for analytical chemists to ensure your results are accurate, precise and reproducible. Every product is meticulously quality-controlled to maintain the integrity of your testing protocols and, with our dedicated scientists, the expertise you need is always on hand.

SAFC_®

The SAFC[®] portfolio of MilliporeSigma offers customized and ready-to-use raw material solutions, backed by deep regulatory expertise. Our high-quality products and services are supported by an experienced and responsive team of raw material and regulatory experts who are committed to understand your requirements and provide tailored solutions that meet your exact needs.

Sigma-Aldrich.

The Sigma-Aldrich[®] portfolio of MilliporeSigma offers a strong and everexpanding offering of lab and production materials. Through our technical support and scientific partnerships, we help connect our customers with a whole world of progress.

BioReliance®

The BioReliance® portfolio of MilliporeSigma encompasses biopharmaceutical characterization, safety testing and process development, as well as clinical and commercial biomanufacturing. Our experienced teams and operational expertise make us the partner who supports you all the way and always has your vital goal in mind.

Milli-Q®

The Milli-Q[®] portfolio of lab water solutions of MilliporeSigma takes care of all your water quality and purity needs. Our solutions are backed by consistent quality and full compliance and work seamlessly together, letting you focus on your vital work.

Our life science portfolio brands have their own unique way of doing things, but all are connected by a common purpose and ambition: solving the toughest problems in life science by collaborating with the global scientific community and accelerating access to solutions that improve health for people everywhere.

Wayne Way, Global Strategy Pharma QC at MilliporeSigma

Tackle biologics development and quality control now! Benefit from our expertise and check out our latest educational content and products <u>here</u>!

List of Acronyms

ACS - American Chemical SocietyGMP - Good Manufacturing PracticeADC - Antibody-Drug ConjugateIGg - Immunoglobulin GATP - Adensosine TriphosphateIND - Investigational New Drug ApplicationDA - DaltonISO - International OrganizationFDA CFR - Federal Drug Administrationfor StandardizationCode of Federal RegulationsJP - Japanese Pharmacopeia

mAb - Monoclonal Antibody PD - Pharmacodynamic PhEur - European Pharmacopeia PK - Pharmacokinetic QC - Quality Control USP - United States Pharmacopeia

Sources

• California Manufacturing Technology Consulting

European Medicines Agency, SME Office

- Pharma Focus Asia
- Merck KGaA, Darmstadt, Germany

© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. 33985 12/2020 Lit. No. MS_FL7107EN

MilliporeSigma 400 Summit Drive Burlington, MA 01803



Created in collaboration with Labiotech.eu